Latest Zidovudine Stories

The journal Science named the HIV Prevention Trials Network 052 study the "2011 Breakthrough of the Year." The study evaluated whether antiretroviral drugs can prevent sexual transmission of HIV among couples in which one partner has HIV and the other does not. The researchers found that early treatment with antiretroviral therapy reduced HIV transmission in couples by 96 percent. "In combination with other promising clinical trials, the results have galvanized efforts to end the...

NIH-funded treatment-as-prevention study heralded as a major advance The journal Science has chosen the HPTN 052 clinical trial (http://www.niaid.nih.gov/news/newsreleases/2011/Pages/HPTN052.aspx), an international HIV prevention trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, as the 2011 Breakthrough of the Year. The study found that if HIV-infected heterosexual individuals begin taking antiretroviral...

The HIV Prevention Trials Network 052 study, led by Myron S. Cohen, MD of the University of North Carolina at Chapel Hill, has been named the 2011 Breakthrough of the Year by the journal Science. HPTN 052 evaluated whether antiretroviral drugs can prevent sexual transmission of HIV among couples in which one partner has HIV and the other does not. The research found that early treatment with antiretroviral therapy reduced HIV transmission in couples by at least 96 percent. The study was...

A clinical trial that revitalized HIV research tops the journal's list of advances in 2011 The journal Science has lauded an eye-opening HIV study, known as HPTN 052, as the most important scientific breakthrough of 2011. This clinical trial demonstrated that people infected with HIV are 96 percent less likely to transmit the virus to their partners if they take antiretroviral drugs (ARVs). The findings end a long-standing debate over whether ARVs could provide a double benefit by...

CHAPEL HILL, N.C., Dec. 22, 2011 /PRNewswire/ -- The HIV Prevention Trials Network 052 study, led by Myron S. Cohen, M.D. of the University of North Carolina at Chapel Hill, has been named the 2011 Breakthrough of the Year by the journal Science. To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/53909-unc-hiv-prevention-research-scientific-breakthrough-of-year (Photo: http://photos.prnewswire.com/prnh/20111222/MM26343 ) HPTN 052...

Discovery offers new research avenues for fighting this global epidemic Gladstone Institutes scientist Nevan Krogan, PhD, today is announcing research that identifies how HIV—the virus that causes AIDS—hijacks the body's own defenses to promote infection. This discovery could one day help curb the spread of the HIV/AIDS pandemic. Dr. Krogan conducted this research in his laboratory at the University of California, San Francisco (UCSF)—a leading medical school with which Gladstone...

Hundreds of connections between viral and human proteins identified in UCSF-led study -- work that may reveal new drug targets In perhaps the most comprehensive survey of the inner workings of HIV, an international team of scientists led by researchers at the University of California, San Francisco has mapped every apparent physical interaction the virus makes with components of the human cells it infects—work that may reveal new ways to design future HIV/AIDS drugs. Explored this...

MILFORD, Mass., Dec. 21, 2011 /PRNewswire/ -- At a ceremony coinciding with the 20th anniversary of Los Angeles Laker Marvin "Magic" Johnson's public revelation that he had acquired HIV, the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences acknowledged Waters Corporation (NYSE: WAT) for its donation of a state-of-the-art ACQUITY® TQD System, a liquid chromatograph/mass spectrometer that will be used to build laboratory capacity and advance...

Among people recently infected with HIV, immediate antiretroviral therapy (ART) appears preferable to deferring treatment, according to a new study published in the Journal of Infectious Diseases and now available online. Although the benefits of ART during early HIV-1 infection remain unproven, the findings support growing evidence favoring earlier ART initiation. Christine Hogan, MD, of the Medical College of Wisconsin in Milwaukee, led a team of researchers from various institutions to...

Scientists have found the 'key' that HIV uses to enter our cells' nuclei, allowing it to disable the immune system and cause AIDS. The finding, published today in the open access journal PLoS Pathogens, provides a potential new target for anti-AIDS drugs that could be more effective against drug-resistant strains of the virus. HIV is transmitted through bodily fluids, primarily infected blood or semen. Once inside the bloodstream, the virus infects key components of the immune system...